Biopharmaceutical Industry Activity Accelerates
The biopharmaceutical sector is experiencing significant activity with major acquisitions, focusing on RNA therapies and rare diseases.
Key players, including BioCryst and Bristol Myers Squibb, are leading the charge in this landscape shift.
- Bristol Myers Squibb
- BioCryst Pharmaceuticals
- AstraZeneca
- Novo Nordisk
BioCryst Pharmaceuticals has announced a definitive agreement to acquire Astria Therapeutics for $700 million in enterprise value.
The acquisition represents an implied value of $13 per share, with unanimous approval from both BioCryst and Astria boards of directors.
Author's summary: Biopharmaceutical industry sees major acquisitions.
More News
- Apparent hackers take over PA systems at 4 North American airports
- Pope Leo gifted with "Proton" a purebred Arabian horse
- Our Opinion: Legislature should leave public notices alone
- Chicago Catholics confront ICE, fear and protests to protect migrants' dignity, religious rights - Catholic Standard
- Lenovo Introduces Custom Legion Radeon RX 9070 XT GPU for Blade 7000P PCs
- Electric Island Expands with Five Shows and a Massive Lineup
- RecTracker: How Indian law firms are hiring from the Batch of 2025 across law schools
- As tenant evictions increase in the Balearics, landlords' legal uncertainty is blamed for high rents
- Hamas Battling Different Clans for Control in Gaza: Who Are These Groups?
- Argility’s fleet management solution transforms fleet maintenance, inventory management for major mining/logistics entity